Nurix Therapeutics: Clinical Wins Offer Asymmetric Upside

2026-01-12 07:42:44 ET

My positive outlook on Nurix ( NRIX ) is not just about the excitement about the mechanism of action of the TPD modality but also the dramatic difference in the duration of response observed in the Phase 1 trial data from Nurix relative to drugs that are currently available to treat these cancers, including pirtobrutinib. The progression-free survival curves and response rate data in the most difficult-to-treat patients clearly demonstrate that bexobrutideg creates a higher ceiling for effectiveness in B-cell malignancies than any other therapy....

Read the full article on Seeking Alpha

For further details see: